Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Weight loss intervention and QoL outcomes in breast cancer: BWEL trial

Jennifer Ligibel • 31 May 2026
ASCO 2026
Breast Cancer
BWEL

Jennifer Ligibel, MD, Dana-Farber Cancer Institute, Boston, BA, examines patient-reported quality of life (QoL) and symptom outcomes from the BWEL trial (NCT02750826) evaluating a lifestyle-based weight loss intervention versus health education alone in patients with stage II–III breast cancer and elevated body mass index. At 6 and 24 months, the weight loss intervention arm demonstrated significantly greater improvements in physical function, global physical and mental health, and fatigue compared with the health education arm alone. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jennifer Ligibel

Acupuncture for managing hot flashes in patients with breast cancer on endocrine therapy
1:01
Acupuncture for managing hot flashes in patients with breast cancer on endocrine therapy
Jennifer Ligibel • 16 Sep 2024
Non-pharmacologic interventions to improve outcomes in breast cancer care
1:42
Non-pharmacologic interventions to improve outcomes in breast cancer care
Jennifer Ligibel • 16 Sep 2024
Impact of weight loss intervention on physical activity in the BeWEL trial
1:46
Impact of weight loss intervention on physical activity in the BeWEL trial
Jennifer Ligibel • 16 Sep 2024

Related Videos

Creating a digital support group for patients with breast cancer in Saudi Arabia
2:11
Creating a digital support group for patients with breast cancer in Saudi Arabia
Atlal Abusanad • 31 May 2026
Pooled analysis of neoadjuvant vs adjuvant chemotherapy in HR+/HER2- breast cancer
2:00
Pooled analysis of neoadjuvant vs adjuvant chemotherapy in HR+/HER2- breast cancer
Oleg Gluz • 1 Jun 2026
Chemotherapy omission in intermediate genomic-risk patients with breast cancer
0:53
Chemotherapy omission in intermediate genomic-risk patients with breast cancer
Oleg Gluz • 1 Jun 2026
Survival analysis data from the TP-II trial in HR+/HER2+ early breast cancer
1:33
Survival analysis data from the TP-II trial in HR+/HER2+ early breast cancer
Oleg Gluz • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals